Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 04, 2025 06:35 ET
|
Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
June 11, 2024 02:00 ET
|
Essential Pharma
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
May 21, 2024 08:00 ET
|
Bionano Genomics
Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
April 09, 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
August 01, 2023 07:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
August 01, 2023 03:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Pr
April 20, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C...
Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain
November 16, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain DelveInsight’s...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
November 30, 2020 07:00 ET
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
November 13, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...